Zura Bio’s (ZURA) “Neutral” Rating Reaffirmed at HC Wainwright

Zura Bio (NASDAQ:ZURA)‘s stock had its “neutral” rating reissued by research analysts at HC Wainwright in a research report issued to clients and investors on Monday, Benzinga reports. They currently have a $5.00 price target on the stock. HC Wainwright’s target price suggests a potential upside of 1.63% from the company’s previous close.

Several other equities analysts have also recently commented on ZURA. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zura Bio in a research note on Friday. Piper Sandler reiterated an “overweight” rating and issued a $26.00 price objective on shares of Zura Bio in a research report on Thursday, September 19th.

Zura Bio Stock Performance

Shares of ZURA stock opened at $4.92 on Monday. Zura Bio has a 12-month low of $2.00 and a 12-month high of $6.35. The company has a 50 day moving average of $3.92 and a 200-day moving average of $3.96.

Zura Bio (NASDAQ:ZURA) last issued its earnings results on Tuesday, August 13th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). On average, sell-side analysts forecast that Zura Bio will post -0.47 EPS for the current year.

Insider Buying and Selling

In related news, Director Someit Sidhu sold 51,728 shares of the stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $3.87, for a total value of $200,187.36. Following the completion of the transaction, the director now directly owns 2,085,418 shares of the company’s stock, valued at $8,070,567.66. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 15.80% of the stock is currently owned by insiders.

Institutional Trading of Zura Bio

A number of institutional investors and hedge funds have recently bought and sold shares of the company. AQR Capital Management LLC purchased a new stake in Zura Bio during the 2nd quarter valued at $43,000. SG Americas Securities LLC purchased a new stake in Zura Bio during the 3rd quarter valued at $62,000. Renaissance Technologies LLC lifted its holdings in shares of Zura Bio by 51.3% during the 2nd quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock valued at $61,000 after buying an additional 5,900 shares during the period. Forefront Analytics LLC increased its position in Zura Bio by 22.1% during the second quarter. Forefront Analytics LLC now owns 41,569 shares of the company’s stock valued at $145,000 after acquiring an additional 7,531 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in Zura Bio by 15.8% in the second quarter. Bank of New York Mellon Corp now owns 47,109 shares of the company’s stock valued at $165,000 after acquiring an additional 6,412 shares during the period. 61.14% of the stock is currently owned by institutional investors.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.